EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines

17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...

Read more →

European Patent Office rules in favour of Sanofi and Regeneron concerning Praluent (alirocumab)

29 October 2020 - Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab). ...

Read more →

AbbVie announces Humira (adalimumab) global patent license with Momenta

6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.  ...

Read more →

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in ...

Read more →

EU Ombudsman confirms EMA’s correct handling of declared interests

24 November 2017 - Latest decision concludes no maladministration at EMA. ...

Read more →

Platform for post-authorisation studies registered as EU trade mark

7 August 2017 - ‘EU PAS Register’ includes more than 1,100 observational post-authorisation studies. ...

Read more →